MSI-H tumors were observed in 5 out of 76 patients (6.6%) with RAF1 aberrations, while MSI-H tumors were found only in 2.1% of wild-type RAF1 cancer patients (p < 0.0001) (Figure 1F). This evidence concerns the gene RAF1 and cancer.